Subscribe today to receive notice of our latest thought leadership, articles, and updates.
Insights
Clinical Connection
Clinical impact on workers' compensation and auto no-fault
Our latest white papers
Caring for workers affected by climate change
Climate change poses significant risks to the workforce. In our recent white paper, we explore the health challenges workers face, and how Optum programs and teams work together to address an injured worker’s varied and often codependent needs.
Read moreObesity in the workforce and GLP-1 medications
Breakthroughs in GLP-1 medications offer substantial health benefits for overweight injured workers. But clinical considerations and regulatory requirements can make authorization decisions more difficult. Our clinical team and policy experts are ready to help you navigate the evolving GLP-1 landscape while also focusing on best-in-class managed care strategies for your injured workers.
Read moreRecent updates
|
February 17, 2022 · Clinical Team
The U.S. Food and Drug Administration (FDA) issued a warning on January 12, 2022, regarding a potential risk of dental problems with orally-dissolving buprenorphine medications. Buprenorphine is a mixed opiate agonist-antagonist used to treat opioid use disorder (OUD) and pain. Read more... |
|
|
February 10, 2022 · Clinical Team
In October 2021, the U.S. Food and Drug Administration (FDA) approved a higher-dose naloxone hydrochloride (HCl) injection - ZIMHI™ (5 mg/0.5 mL) - to treat opioid analgesic overdose. ZIMHI is designed to be administered in the muscle (intramuscular) or under the skin (subcutaneous) using a single-dose, prefilled syringe that delivers 5 mg of naloxone HCl solution. Read more... |
Page 3 of 4